地舒单抗治疗骨质疏松诱发低钙血症的真实世界预测因素
该回顾性研究基于大型健康维护组织2010-2018年病历,纳入2005例社区骨质疏松患者(93%女性,平均76±9岁),发现地舒单抗治疗期间低钙血症发生率为7.4%,其中1%低于8 mg/dL。治疗前白蛋白校正血钙和肌酐水平是主要预测因素,血钙监测可能有助于识别和预防严重低钙血症。
要点
- 真实世界地舒单抗相关低钙血症发生率为7.4%,高于临床试验报告的0.05-1.7%。
- 治疗前白蛋白校正血钙和肌酐水平是低钙血症的最强预测因素。
- 基线血钙≤9.31 mg/dL预测低钙血症的敏感性77%、特异性56%。
核心结论
- 真实世界地舒单抗诱导的低钙血症发生率高于既往报告。
- 低钙血症可能在持续治疗中每次地舒单抗给药后发生。
- 需要充足的钙和维生素D补充,高危患者建议监测血钙以早期发现严重低钙血症。
研究设计与样本
- 回顾性分析基于大型健康维护组织2010-2018年病历。
- 纳入2005例社区骨质疏松患者,93%为女性,平均年龄76±9岁。
- 低钙血症定义为白蛋白校正血钙浓度低于8.5 mg/dL。
主要发现
- 149例(7.4%)治疗期间发生低钙血症,其中1%低于8 mg/dL。
- 低钙血症发生时间:66例在0.5-1年,48例在1-2年,35例在超过2年。
- 低钙血症组与正常血钙组治疗前白蛋白校正血钙分别为9.1±0.4 vs. 9.4±0.5 mg/dL(p<0.05)。
- 低钙血症组与正常血钙组治疗前肌酐分别为0.9±0.5 vs. 0.8±0.3 mg/dL(p<0.05)。
- 低钙血症发生率随eGFR下降而升高(eGFR范围间差异p=0.032)。
关键数值与推荐
- 基线血钙水平≤9.31 mg/dL预测低钙血症的敏感性为77%、特异性为56%。
- 模型(-2)×钙+肌酐预测低钙血症:低于-17.4时发生率3.7%,高于-17.4时17.1%。
- 性别、年龄、25-羟基维生素D、甲状旁腺激素、碱性磷酸酶及地舒单抗作为一线或进阶治疗均无预测价值。
临床怎么用
- 对社区骨质疏松患者使用地舒单抗前应评估血钙和肌酐水平。
- 高危患者(如基线血钙偏低或肾功能下降)建议监测血清钙。
- 确保充足的钙和维生素D补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hypocalcemia was reported at low rates (0.05-1.7%) in denosumab-treated postmenopausal women with osteoporosis. This real-life study shows a 7.4% rate of denosumab-induced hypocalcemia in community-dwelling osteoporotic men and women. Pretreatment serum calcium and creatinine levels are major predictors for this complication. Serum-calcium monitoring may help to identify and prevent severe hypocalcemia. PURPOSE: RCTs have reported a 0.05-1.7% rate of hypocalcemia in denosumab-treated postmenopausal women with osteoporosis, but long-term real-life data are lacking. We assessed the rate of hypocalcemia in osteoporotic community-dwelling patients treated with denosumab. METHODS: A retrospective analysis was conducted based on medical records (2010-2018) from a large HMO. An albumin-adjusted serum calcium concentration lower than 8.5 mg/dL was defined as hypocalcemia. RESULTS: We included 2005 patients (93% women, mean age 76 ± 9 years). Hypocalcemia developed during treatment in 149 patients (7.4%; 1% less than 8 mg/dL): in 66 after 0.5-1 years; 48 after 1-2 years; 35 after > 2 years. On comparison of the hypocalcemic and normocalcemic patients, the strongest predictors of hypocalcemia were pretreatment levels of albumin-adjusted serum calcium (9.1 ± 0.4 vs. 9.4 ± 0.5 mg/dL, respectively; p < 0.05) and creatinine (0.9 ± 0.5 vs. 0.8 ± 0.3 mg/dL, respectively; p < 0.05). The hypocalcemia rate increased in parallel to a decrease in eGFR (p = 0.032 for the difference between eGFR ranges). Baseline calcium level ≤ 9.31 mg/dL predicted hypocalcemia with a sensitivity of 77% and specificity of 56%. A model of (- 2)*calcium + creatinine predicted hypocalcemia (3.7% when lower and 17.1% when higher than - 17.4). Gender, age, 25-hydroxyvitamin-D, parathyroid hormone, alkaline phosphatase, and whether denosumab was given as first or advanced line of osteoporotic therapy had no predictive value. CONCLUSION: Real-life rates of denosumab-induced hypocalcemia are higher than previously reported. Hypocalcemia might develop after each dose of denosumab in ongoing treatment. Adequate calcium and vitamin D supplementation are needed. Serum calcium monitoring is advised in high-risk patients for early detection of severe hypocalcemia.
引用
- Tsvetov G, Amitai O, Shochat T, et al. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int. 2019. PMID: 31838550. doi:10.1007/s00198-019-05261-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。